V entilator-associated pneumonia (VAP) constitutes a frequent infection in intensive care unit (ICU) patients, and its frequency increases proportionally to the duration of ICU stay (1-4). Previous studies have shown that patients who experience VAP may have a greater risk of death compared to patients without the disease (5-7).
V entilator-associated pneumonia (VAP) constitutes a frequent infection in intensive care unit (ICU) patients, and its frequency increases proportionally to the duration of ICU stay (1) (2) (3) (4) . Previous studies have shown that patients who experience VAP may have a greater risk of death compared to patients without the disease (5-7).
In this respect, several strategies have been introduced to minimize the risk and to manage VAP effectively, such as application of adequate antibiotic protocols, bacterial decontamination of the oropharyngeal cavity, head positioning, and early gastrostomy (8 -12) .
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) present anti-inflammatory and immunomodulatory effects besides their ability to regulate cholesterol composition (13) (14) (15) . It has been therefore hypothesized that these pleiotropic characteristics of statins might also be useful in the management of various diseases (15) (16) (17) (18) (19) . Indeed, recent studies showed that treatment with statins was associated with reduced risk of pneumonia (20, 21) . However, the relationship between the use of statins and the risk of pneumonia is not consistent (22) . In addition, previous studies (20 -22) that investigated this relationship between statins and the frequency/ outcome of pneumonia were observational studies that included patients who were already on statins for cholesterol regulation. In contrast, there is a lack of interventional studies investigating whether statins are able to affect the frequency of severe forms of pneumonia, such as VAP.
Objective:
To investigate whether the use of pravastatin reduces the frequency of ventilator-associated pneumonia and whether it is related to favorable outcomes in critical care patients.
Design: Two-center, two-arm, randomized, open-label, controlled trial.
Setting: University Hospital and General Hospital of Larissa, Greece. Patients: Consecutive patients were recruited from the intensive care units of the two hospitals. Patient inclusion criteria included mechanical ventilation and intensive care unit stay of >48 hrs.
Interventions: The two arms consisted of treatment plus oral pravastatin sodium (40 mg) (n ‫؍‬ 71 patients, pravastatin group) and treatment without pravastatin (n ‫؍‬ 81 patients, control group). Treatment was started after randomization and ended 30 days later.
Measurements and Main Results: Ventilator-associated pneumonia frequency and intensive care unit mortality at 30 days and at the end of intensive care unit stay were measured. Adverse events related to statin treatment in the intensive care unit were documented. Sixteen patients (22.5%) in the pravastatin group and 28 (34.5%) in the control group (p ‫؍‬ .11) presented pneumonia during the 30-day treatment period in the intensive care unit. There was an indication for increased probability of being free from ventilator-associated pneumonia during the 30-day treatment period in the pravastatin group compared to the control group (p ‫؍‬ .06) and significantly increased probability during the whole intensive care unit period of stay (p ‫؍‬ .04) in the pravastatin group compared to the control group in the subgroup of patients with Acute Physiology and Chronic Health Evaluation scores of >15. Six patients (8.45%) in the pravastatin group and 16 (19.85%) in the control group died during the 30-day treatment period (p ‫؍‬ .06), whereas 10 (14.1%) patients in the pravastatin group and 24 (29.1%) patients in the control group died during the whole period of intensive care unit stay (p ‫؍‬ .03). Pravastatin group patients with Acute Physiology and Chronic Health Evaluation scores of >15 had significantly increased probability of survival compared to controls during the 30-day treatment period (p ‫؍‬ .04). Creatine kinase and hepatic function enzyme levels during the whole study period were not significantly different between the pravastatin group and control group.
Conclusion: This study provides evidence that pravastatin may favorably affect the outcome of critical care patients. (Crit Care  Med 2011; 39:2440 -2446) KEY WORDS: critical care; mechanical ventilation; pneumonia; statin; survival We therefore conducted a randomized study to investigate whether the addition of statins in the usual treatment of ICU patients who were not previously on statins can reduce the frequency of VAP or can affect the outcome of critically ill patients.
MATERIALS AND METHODS
Design and Population. The present study is a two-center, two-arm, randomized, openlabel, controlled trial. The decision for openlabel design was based on the Ethics Committee's argument of lack of safety and efficacy data on statin administration in critical care patients. Consecutive sampling was used to recruit critical care patients. Inclusion criteria were age of Ͼ18 yrs, use of mechanical ventilation for Ͼ48 hrs, and ICU stay of Ͼ48 hrs. Previous use of statins or agents that affect statin metabolism, any contraindication to statins, serum creatine kinase of more than three times the upper normal limit at admission in nontrauma patients, malabsorption, active pneumonia, and pregnancy were exclusion criteria from the study. Two hundred seventy-nine subjects hospitalized during the recruitment period were assessed for eligibility. The study took place at the ICU of the University Hospital of Larissa and the General Hospital of Larissa in Greece (20 beds in total) between June 2008 and January 2010.
One hundred fifty-two of the subjects were eligible and were randomized to either receive statin per os (pravastatin sodium, 40 mg) or not receive it (pravastatin group [PG] and control group [CG], respectively) ( Fig. 1) . Randomization (stratified by center) was performed with the use of random numbers (23) . The trial medication was received for 30 days. The study was approved by the Internal Review Board and Ethics Committee of the University Hospital and the General Hospital of Larissa, and informed consent was obtained by the patient or the next of kin.
Outcomes. We primarily assessed the cumulative frequency of VAP calculated at the end of pravastatin treatment. In addition, we secondarily assessed the cumulative frequency of VAP at ICU discharge, mortality at the end of pravastatin treatment, and overall ICU mortality; furthermore, we assessed the mechanical ventilation duration, occurrence of adverse events potentially related to treatment (creatine kinase abnormal changes, hepatic enzyme dysfunction), evolution of inflammatory markers, and antibiotic-free days in both groups.
On the basis of a VAP occurrence rate of 44.5%, which was documented in a previous study conducted at the University Hospital of Larissa (11), a sample of at least 152 subjects was needed to observe a 50% reduction of VAP at a 5% significance level with 80% power. For a worst-case scenario of 40% reduction of VAP frequency, the enrollment of 240 subjects would be required (␣ ϭ .05, power 80%); the inclusion of 300 patients would then provide us with a safety margin of 25% in that case. An independent data and safety monitoring board periodically reviewed efficacy and safety data, and a formal interim analysis of efficacy was performed when 50% of the expected number of primary events had accrued. On the basis of the interim analysis results, which suggested that the best scenario could be satisfied, and due to a relatively low enrollment rate, the data-monitoring committee advocated to complete the study after the enrollment of 152 patients.
Clinical Assessment and Microbiology. Baseline assessment included evaluation of demographic data, medical history, radiography of the thorax, blood leukocyte count, PaO 2 / FIO 2 , maximum body temperature of the day, C-reactive protein serum level, human leukocyte antigen cell receptor expression, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment score, and Murray score (24, 25) .
VAP diagnosis required new persistent chest-radiographic infiltrates in conjunction with either a positive blood or pleural fluid culture or two of the following: fever (temperature of Ͼ38.3°C), leukocytosis (leukocyte count of Ͼ10 4 cells/mm 3 ), and purulent tracheal aspirate. In addition, a positive tracheal aspirate culture (Ն10 5 colony-forming units/ mL) or bronchoalveolar lavage (BAL) culture (Ն10 4 colony-forming units/mL) was required to confirm the diagnosis of VAP (1).
To determine bacterial species responsible for pneumonia, bronchial secretions or BAL was sampled at the baseline and at the fifth, tenth, and 20th days of admission, at the day of clinical diagnosis of VAP, and at ICU discharge. Samples of bronchial secretions, BAL, or other biological fluids were also collected at any other day if the attending physicians found it clinically relevant according to the established protocol (26) . Microbiology assessment included identification and quantitative assessment of the responsible agent and evaluation of its in vitro resistance to antibiotics.
Measures for preventing nosocomial infections and the treatment strategy for VAP or sepsis followed standard protocols in both institutions based on accepted guidelines (27, 28) . The oropharyngeal cavity was cleaned four times a day with chlorhexidine solution. The ventilator circuit was not changed routinely. Patients were kept in a semirecumbent position during mechanical ventilation. The tracheal cuff pressure was maintained at 25 cm H 2 O. Other protocols included isolation techniques, antibiotic treatment based on local microbiological data, continuous surveillance of nosocomial infections, guidelines for use of care bundles/high-impact interventions, staffing levels, use and disposal of personal protective equipment, planned monitoring of cleaning standards, and clear visiting arrangements. On the basis of data collected during the study, there were no significant differences in compliance between the two centers in evaluated terms (application of isolation criteria [ tidisciplinary ICU meetings in each hospital. Clinical follow-up continued for up to 6 months from the initiation of the study to document late adverse events related to the study.
Statistical Analysis. All analysis was performed on an intention-to-treat basis. Data between the PG and CG were compared using Fisher's exact test for categorical variables, and the t test or Mann-Whitney test was used as appropriate for continuous variables. Differences in changes of inflammatory markers (dependent variables) during time were analyzed by using a general linear model for repeated measures with Bonferonni's adjustment. The probability of being free from VAP in the ICU in treated patients and controls and the probability of ICU survival were assessed with Kaplan-Meier survival analysis, and comparisons between groups were performed using the log-rank (Mantel-Cox) test. Cox proportional hazards regression analysis was also used to examine the effect of multiple risk factors on mortality; factors associated significantly (p Ͻ .05) with mortality in univariate analyses were entered in multivariable analyses. The statistical tests were two sided. A result was considered statistically significant when p Ͻ .05. Analysis was performed using statistical software, SPSS version 15 (IBM, Somers, NY) for Windows (Microsoft, Redmond, WA).
RESULTS
One hundred fifty-two eligible patients were recruited and randomized (Fig. 1) . All 152 patients were included in the final analysis. Table 1 represents prerandomization characteristics of the patients. The overall mean (SE) age was 56 (1.4) yrs. There were 106 males (70%). The median APACHE II score was 15.
Cholesterol levels at the baseline in the PG and CG were 153 (12) and 127 (16) , respectively (p ϭ .7). Creatine kinase (mg/dL) mean (SE) levels at the baseline and at the fifth, tenth, 20th, and 30th days of treatment in the PG and CG were 659 (185) vs. 514 (121) (15) , (p ϭ .2), respectively. During the treatment period, creatine kinase levels increased temporarily by Ͼ500% from the baseline value in nine subjects (12.6%) in the PG and in 13 patients in the CG (16%) (p ϭ .65). Hepatic function enzymes at admission and during the whole study period were not significantly different between the PG and CG. Evolution of inflammatory markers assessed during the study was not significantly different between the PG and CG: white blood cell count (p ϭ .12), C-reactive protein level (p ϭ .3), and human leukocyte antigen cell receptor expression (p ϭ .6) (Fig. 2) .
The length of stay (days) in the ICU was overall 23.1 (1.5), and was similar in the PG and CG 21.9 (2.1) and 24.3 (2.2), respectively (p ϭ .72). The mechanical ventilation durations (days) in the PG and CG were 19.4 (2.5) and 21.5 (2.2), respectively (p ϭ .64). Antibiotic-free days through the 30-day treatment period in the PG and CG were 2.2 (0.6) and 1.9 (0.7), respectively (p ϭ .65).
VAP. Sixteen patients (22.5%) in the PG and 28 (34.5%) in the CG (p ϭ .11, Fisher's test) presented pneumonia during the 30-day treatment period in the ICU. Although there was an indication of a trend toward a higher probability of being free from VAP during the 30-day treatment period in the PG compared to the CG, the difference was not significant (Fig. 3) . ICU Mortality. Six patients (8.45%) in the PG and 16 (19.85%) in the CG died during the 30-day treatment period (p ϭ .06, Fisher's test), whereas ten patients (14.1%) died in the PG and 24 (29.1%) patients died in the CG during the whole period of ICU stay (p ϭ .03). There was an indication for increased probability of survival in the PG compared to the CG during the 30-day treatment period and during the whole ICU stay; the differences did not reach formal statistical significance (p ϭ .07 and p ϭ .07). Cox regression analysis for the effect of multiple factors on mortality revealed the following: PG group hazard ratio (95% confidence interval), 0.45 (0.17-1.12) (p ϭ .10), APACHE II score 1.12 (1.04 -1.22) (p ϭ .004), age 1.01 (0.99 -1.04) (p ϭ .18), Sequential Organ Failure Assessment score 1.07 (0.82-1.17) (p ϭ .6). At the 6-month follow-up, 28 (39.4%) and 32 (39.5%) patients had died in the PG and CG, respectively (p ϭ .75).
Ancillary Analyses. On the basis of available evidence suggesting that the outcome in critical care patients might vary across baseline risk (29), we further analyzed our data based on the basis of the APACHE II score (Table 3 ). There were no discernible differences between the PG and CG in the subgroup with APACHE scores of Ն15. When data were stratified according to the median APACHE score, we found that there was an indication for increased probability of being free from VAP during the 30-day treatment period in PG compared to CG patients with APACHE scores of Ն15 (p ϭ .06) and significantly increased probability during the whole ICU period (p ϭ .04) (Fig. 4) . Furthermore, we found that PG patients with APACHE scores of Ն15 had significantly increased probability of survival compared to controls during the 30-day treatment period (p ϭ .04); being in the PG group was the only factor associated with mortality among multiple factors assessed. Patients with APACHE scores of Ն15 had marginally increased probability during the whole ICU period (p ϭ .06) (Fig. 5) .
DISCUSSION
The present study provides evidence that the addition of oral pravastatin in the usual treatment regime of ICU patients might have significant effects on VAP frequency and ICU mortality, especially in more severely ill ICU patients. Our data suggested that patients with APACHE II scores of Ն15 who received statin presented an indication for increased probability of being free from VAP during the 30-day treatment period (p ϭ .06) and significantly increased probability during the whole ICU period (p ϭ .04) compared to the controls. Notably, in PG patients with APACHE II scores of Ն15, the probability of survival during the 30-day treatment period was increased compared to that of the controls (p ϭ .04). These findings suggest that statins may be useful as an adjunctive therapy in critically ill patients. In this respect, our results support the findings of previous studies that suggested that statins may favorably affect the course of critically ill patients (19, 30) . Two previous studies examined the progression of community-acquired pneumonia in patients receiving statins for lowering cholesterol compared to patients who were not on statins and demonstrated that the use of statins was associated with a decreased mortality rate and a significantly reduced risk of fatal pneumonia (19, 30 -32) . Mortensen et al (30) found that the use of statins was strongly related to a decreased 30-day mortality rate due to community-acquired pneumonia. Frost et al (31) found that statin use was associated with a statistically significant reduced risk of influenza/pneumonia death in chronic obstructive pulmonary disease patients, whereas another investigation (29) showed that statin use was associated with a reduced risk of fatal pneumonia. Those previous studies demonstrated a beneficial effect of the prior statin use on the course and outcome of patients with pneumonia. In contrast, a large prospective study came to a different conclusion, suggesting a potentially harmful risk of statins (22) . However, it should be pointed out that those previous studies were either retrospective or prospective with an observational design and, most importantly, they included patients who had already been on chronic statin treatment for cholesterol regulation. In the present study, we evaluated the effect of statins on VAP frequency by adding pravastatin to the usual treatment of ICU patients, and to avoid results misinterpretation, we excluded from the study all patients who were already on statins. To the best of our knowledge, this is the first randomized study that provides evidence supporting that statins might affect the frequency of VAP and the course of critically ill patients.
Our findings suggested that patients on pravastatin with APACHE scores of Ն15 had marginally increased probability of being free from VAP and significantly increased probability of survival compared to the controls during the 30-day period of treatment (Figs. 4 and 5) . We assume that this might be explained by potential "anti-inflammatory" or "antiinfectious" capability of statins, which may reduce the inflammatory burden of the most severe forms of critical illness. This hypothesis can be based on available evidence from previous studies suggesting that statins present anti-inflammatory properties that can influence the immune and inflammatory response associated with sepsis and critical care illness (15, (33) (34) (35) . These properties include down-or up-regulation of cytokines, modification of the function of leukocytes and lymphocytes, and direct inhibition of major histocompatibility complex II (33, 34) . Furthermore, it was previously reported that statins can cause an increase in heme oxygenase activity and may reduce the oxidative burden in tissues during sepsis (35) . Therefore, statins may modify the inflammatory cascade and inhibit the progression of septic conditions. Furthermore, statins or their metabolites may present antimicrobial effects or may affect the virological response, although the mechanisms are under investigation (36, 37) ; notably, the statin minimum inhibitory concentration has been measured for methicillinresistant S. aureus (37) . Our results demonstrated a beneficial effect of statins on survival of most severely ill ICU patients and in this respect are in agreement with the potential anti-infectious properties of statins.
Certainly, we acknowledge that our findings are derived from a subgroup analysis that was not prespecified, and it should be pointed out that our study was not powered to test for treatment-bysubgroup interaction. However, there were no discernible differences between the two treatment groups in the subgroup with APACHE scores of Ͼ15; thus, covariate balance from randomization may still hold in that subgroup. Future investigations can build on this study's findings and be prospectively powered for testing an interaction between treatment and APACHE (or some other severity index) score.
It should also be noted here that evolution of inflammatory markers assessed in this study was not different between the PG and CG. This could be explained either because the population of patients who presented VAP was small or because statins might affect the inflammatory cascade in pathways that have not been assessed in this study. In this investigation, we mainly followed the evolution of clinical and biological inflammatory markers that are commonly used in the ICU, and we have not assessed specific pathways that have been reported to be affected by statins (33, 35) . These points should be taken into consideration in the interpretation of our results.
In the present study, we used pravastatin, which is metabolized enzymatically in the liver cytosol, in contrast to other statins that undergo extensive microsomal metabolism by the cytochrome P450 isoenzyme systems. In this respect, pravastatin may be less subject to interaction with other drugs, and consequently, it may be more suitable for critically ill patients. We assessed creatine kinase changes and liver enzymes daily to evaluate the safety of statin use in the ICU setting. This is important since the safety of statins in the ICU population has not yet been prospectively assessed. Previously reported adverse events (increases in creatine kinase and myopathy) have raised concerns about the safety of statins (22) , although serious events (creatine phosphokinase of more than ten times the upper limit of normal or rhabdomyolysis) were not reported in those studies. Such serious adverse events did not occur in the present study, and creatine kinase elevations occurred in both the PG and CG. Our results regarding hepatic function were similar. It should also be noted that statins have also been discriminated for myopathy. In the present study, critical care neuromyopathy was assessed clinically. No difference was found between the PG and CG. In addition, no significant difference was found in terms of ICU stay or duration of mechanical ventilation, which could reflect critical care neuromyopathy in the PG and CG.
Our findings suggest decreased mortality and VAP rates in patients treated with statins compared to the controls. However, there are certain points that have to be underlined. This study included a general ICU population from two closely located centers that serve a large semiurban area in Greece. The design of our study had to respect several local protocols and medical practices in the two hospitals that participated in the study. Some risk factors for VAP, such as the frequency of patients transfer outside the ICU for examinations (i.e., computed tomography), may not have been assessed, although other factors, such as bed positioning or cuff pressure regulation of the orotracheal tube, have been controlled as much as possible. However, we assessed several factors with known clinical significance, including baseline patient characteristics, comorbidities, parameters of respiratory function, and indices of illness severity.
Criteria used for VAP diagnosis in the present study were in part clinical, and thus, they may be not accurate. Certainly, the definition of VAP diagnosis is still an issue of discussion, and the accuracy of the diagnosis of VAP has been previously investigated on the basis of clinical findings, autopsy findings, and quantitative cultures with/without protected specimen brush/BAL; however, there is a lack of a solid definition (38) . In this respect, one might argue that diagnostic challenges in VAP may affect the results in an open-label study. We certainly acknowledge these limitations. However, in our study, we used a generally accepted definition based on quantitative culture techniques of endotracheal aspirates/BAL that have an acceptable overall diagnostic accuracy (1), and the same criteria were applied in both groups. These diagnostic criteria are applied widely in medical practice, and previous studies used a similar methodology (39 -41) . To increase the accuracy of the diagnosis, patients were screened daily for the presence of VAP. We found a 30-day occurrence rate of 28.9% (32.2% during the whole duration in ICU), which is less than that expected on the basis of results from a former study conducted in Greece but similar to previously reported rates where clinical and microbiological data were used for diagnosis (40, 41) .
In conclusion, the present investigation is the first randomized, open-label study that assessed the impact of adding a statin (pravastatin) in the usual treatment of critically ill patients on VAP frequency. The study included patients who had not received statins in the past. Our findings suggest that pravastatin treatment in the ICU is safe and it might have a beneficial role in the frequency of VAP and in the outcome of critical care illness, especially in patients with more severe illness, such as those with APACHE II scores at admission of Ն15. Data are presented as mean (SE) unless otherwise indicated.
